Biotechnology firm Awakn Life Sciences has secured UK government funding to accelerate the route to the UK and US markets for its proprietary ketamine-assisted therapy, which is designed to treat alcohol use disorder.
Awakn will be working with global clinical research association Veristat, which specialises in accelerating client therapies through the clinical development process and regulatory approval.
...
Need help?
Contact a sales representative right now and don’t wait
“ UK government to fund research into psychedelic treatment for alcoholism ”
Buy report request information:
“ UK government to fund research into psychedelic treatment for alcoholism ”
Biotechnology firm Awakn Life Sciences has secured UK government funding to accelerate the route to the UK and US markets for its proprietary ketamine-assisted therapy, which is designed to treat alcohol use disorder.
Awakn will be working with global clinical research association Veristat, which specialises in accelerating client therapies through the clinical development process and regulatory approval.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
